Categories: Technology

Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

 | Source: Definitive Healthcare Corp.

FRAMINGHAM, Mass., March 04, 2025 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of two senior leaders, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare’s Board of Directors granted inducement awards. The Committee granted Kate Hastings, Definitive Healthcare’s new Chief Customer Officer an inducement award consisting of 172,414 time-based restricted stock units (“RSUs”) effective March 3, 2025 and granted Benjamin Graboske, Definitive Healthcare’s new EVP, Technology, Engineering and Chief Data Officer an inducement award consisting of 1,018,330 time-based RSUs, effective March 3, 2025. Each of these awards was individually negotiated and was granted as an inducement material to Ms. Hastings’ and Mr. Graboske’s respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

Each of the awards is subject to the terms and conditions of Definitive Healthcare’s 2023 Inducement Plan (the “Plan”) and the terms and conditions of an applicable award agreement covering the grant.

Ms. Hastings’ RSUs will vest as follows, subject to Ms. Hastings’ continued employment through each such date: (i) 25% will vest on February 1, 2026; (ii) the remainder will vest in quarterly installments equal to 6.25% of the total RSUs over the subsequent 3 years, until fully vested.

Mr. Graboske’s RSUs will vest as follows, subject to Mr. Graboske’s continued employment through each such date: (i) 25% will vest on April 1, 2026; (ii) the remainder will vest in quarterly installments equal to 6.25% of the total RSUs over the subsequent 3 years, until fully vested.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com 
646-277-1251

Media Contact:
Bethany Swackhamer
bswackhamer@definitivehc.com 

GlobeNews Wire

Recent Posts

Taxpayers Protection Alliance: 20 Years Later, WHO’s Tobacco Control Framework Draws Criticism, Not Celebration

WASHINGTON, April 28, 2025 /PRNewswire/ -- As the World Health Organization (WHO) marks the 20th anniversary…

2 hours ago

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare…

2 hours ago

Comac Medical Announces New Leadership Appointments and International Expansion

Leadership transition and strategic growth initiatives mark the next phase of Comac Medical's development under…

2 hours ago

Forward Networks Named Winner of the Global InfoSec Awards For The Third Year In A Row

Forward Networks Wins the Trailblazer Compliance Award In 13th Annual Global InfoSec Awards at RSAC…

6 hours ago

2024 Global Semiconductor Materials Market Posts $67.5 Billion in Revenue, SEMI Reports

MILPITAS, Calif., April 28, 2025 /PRNewswire/ -- Global semiconductor materials market revenue increased 3.8% to…

6 hours ago

KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS

THE WORLD'S MOST PRESTIGIOUS OSTEOARTHRITIS SOCIETY (OARSI) HELD FOR THE FIRST TIME IN KOREA  LONG-TERM…

6 hours ago